United States: FDA Final Guidance Confirms Role of Medical Device Firms in Cybersecurity Management

On October 2, 2014, the Food and Drug Administration ("FDA") released the final version of a guidance document entitled, "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices." As discussed in a previous Ropes & Gray Alert, the draft guidance released in June 2013 provided recommendations for the development and documentation of cybersecurity management in medical device premarket submissions. Although FDA made some organizational changes in the final guidance, the substance is similar to the draft. Device manufacturers should review this guidance document closely and consider its implications for the design of their current products as well as future premarket submissions.

Cybersecurity Vulnerabilities and Government Initiatives to Address Them

As detailed in Ropes & Gray's prior Alert, last year's draft guidance was accompanied by an FDA safety alert recommending that device manufacturers and health care facilities take steps to assure that appropriate safeguards are in place to reduce the risk of device failure due to cyberattack. Although FDA has not identified any specific instances of patient injuries or deaths associated with cybersecurity incidents, the agency noted that it was aware of specific cybersecurity vulnerabilities, such as the presence of malware on hospital computers and mobile devices and a lack of timely security updates and software patches (particularly for older devices).

FDA's final guidance for device manufacturers also follows on several government-wide orders and initiatives to strengthen cybersecurity. In February 2013, the President issued Executive Order 13636 and Presidential Policy Directive 21, which recognize that public and private stakeholders must enhance the cybersecurity and resilience of the nation's critical infrastructure, including the healthcare and public health sector. Executive Order 13636 also called for the National Institute of Standards and Technology ("NIST") to develop a framework intended to reduce cybersecurity risks to critical infrastructure. The initial version of the NIST's framework, released in February 2014, provides a structure that organizations can use to create, guide, assess, and improve comprehensive cybersecurity programs. FDA's final guidance incorporates several key principles of the NIST's framework, as noted further below.

FDA's Recommendations on Cybersecurity Management

The final guidance identifies cybersecurity-related issues that manufacturers "should consider in the design and development" of medical devices and in preparing premarketing submissions. Specifically, the guidance recommends that manufacturers establish cybersecurity-related design inputs and develop a cybersecurity vulnerability and management approach as part of the risk analysis required under 21 C.F.R. § 820.30(g) of the Quality System Regulation.

The final guidance describes a flexible approach with respect to the particular security controls that are appropriate for a particular device, taking into consideration, among other factors, the device's intended use, its intended environment of use, the type of cybersecurity vulnerabilities present and likelihood of exploitation, and the probable risk of patient harm due to a cybersecurity breach. While the examples of security controls described in the final guidance are essentially the same as those set forth in the final guidance, FDA has reorganized these controls based on the five "core" cybersecurity functions described in the NIST's framework: Identify, Protect, Detect, Respond, and Recover.

In response to the draft guidance, some device manufacturers and industry trade groups acknowledged that cybersecurity-related documentation should be included in device design history files, but argued that such information should not be required in premarket submissions. It is unclear, for example, how the inclusion of such information would be relevant to the "substantial equivalence" standard for FDA clearance of a premarket notification submission under section 510(k) of the Federal Food, Drug, and Cosmetic Act. Nonetheless, FDA maintained its position in the final guidance that device premarket submissions should include cybersecurity-related information, including, among other things, a hazard analysis pertaining to cybersecurity risks, a traceability matrix linking specific cybersecurity risks to specific controls, and a plan for providing software updates and patches as needed throughout the lifecycle of the device.

Notably, the final guidance places less emphasis on confidentiality considerations than the draft guidance. Whereas the draft guidance stated that manufacturers should assure cybersecurity to maintain the "confidentiality, integrity, and availability" of medical device information, this statement was removed from the final guidance.1 As finalized, the guidance contains a definition of "confidentiality," but the term is not used elsewhere in the document. This revision perhaps reflects FDA's recognition that confidentiality and patient privacy considerations are not a core FDA concern, but rather are addressed by privacy laws enforced by other agencies. For example, device manufacturers acting as business associates to entities covered by the Health Insurance Portability and Accountability Act (HIPAA), such as hospitals and physician offices, must comply with applicable requirements of the HIPAA Security and Privacy Rules and are subject to direct liability for any violations of such rules.

Consequences for Medical Device Manufacturers

A clear message from FDA's guidance is that manufacturers that have not already done so should incorporate cybersecurity considerations into their design control procedures. Manufacturers should also expect questions from FDA regarding their risk analysis of cybersecurity considerations during the agency's review of premarket submissions. Moreover, manufacturers should evaluate whether any security enhancements are warranted for their currently marketed devices.

One aspect of the cybersecurity risk analysis that FDA recommends device manufacturers undertake is an identification of "residual" risks that cannot be directly mitigated by device design features. This aspect of the guidance recognizes that device security cannot be assured entirely by manufacturers, but is instead a "shared responsibility between stakeholders, including health care facilities, patients, providers, and manufacturers of medical devices." 

The release of FDA's final guidance comes a week after FDA's announcement of a public workshop to be held on October 21-22, 2014, to discuss collaborative approaches for medical device and healthcare cybersecurity. The public workshop will seek broad input from the healthcare and public health sector on the development of processes and best practices to strengthen medical device cybersecurity. As the announcement of this workshop illustrates, implementing FDA's final guidance is likely to involve a learning process for both device manufacturers and the agency.

Ropes & Gray will continue to monitor developments in this area. If you have any questions, please contact any member of Ropes & Gray's FDA regulatory practice or your usual Ropes & Gray Advisor.

1 Curiously, the Federal Register notice announcing the availability of FDA's final guidance still includes the "to maintain information confidentiality, integrity, and availability" language.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions